

03 May 2012

'RESEARCH NEVER STOPS'

info@evotec.com | www.evotec.com

For further information,
please contact

Dr Werner Lanthaler
Chief Executive Officer
+49.(0)40.560 81-242
+49.(0)40.560 81-333 Fax
werner.lanthaler@evotec.com

Evotec AG
Manfred Eigen Campus
Essener Bogen 7
22419 Hamburg (Deutschland)

Evotec AG announces multi-year agreement with The United States Environmental Protection Agency (EPA)

Hamburg, Germany – 03 May 2012: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today announced that Evotec has entered into a multi-year compound management agreement with the United States EPA. The contract covers a period of five years and has a total value of up to €7.7 million (approx. USD 10 million).

Under the agreement Evotec, through its San Francisco operations, will provide chemical procurement, analysis, sample preparation, and management services in support of the EPA's National Computational Center for Toxicology (NCCT). Services provided will support bioactivity profiling of the EPA's ToxCast™ (Prioritization of Environmentally Relevant Chemicals) Compound Library.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "We are very pleased that the United States EPA has again chosen Evotec to manage its compound collection in support of the National Computational Center for Toxicology (NCCT). This follows from our initial contract with the EPA signed in 2007. Providing key, efficient scientific infrastructures such as Compound Management is a key element of Evotec Execute and we look forward to supporting the EPA's ongoing effort to predict potential toxicity of environmental chemicals. This contract provides further long-term revenue and profitability for Evotec's important compound management services in San Francisco which was acquired from BioFocus in 2011."

ABOUT EVOTEC AG

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Genentech, Medimmune/Astra Zeneca, Novartis and Ono Pharmaceutical. In addition, the Company has existing development partnerships and product candidates both in clinical and preclinical development. These include partnerships with Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes, and with Roche in the field of Alzheimer's disease. For additional information please go to www.evotec.com.

ABOUT EPA'S CHEMICAL SAFETY RESEARCH

EPA's Computational Toxicology Research (CompTox) is part of the broader [Chemical Safety for Sustainability Research Program](#). CompTox is researching ways to address several longstanding difficulties with managing the safety of

chemicals, particularly in assessing chemicals for potential risk to human health and the environment. For example, there are over 80,000 chemicals in the Toxic Substance Control Act (TSCA) Inventory and only a small number have extensive toxicity testing information. Traditional chemical toxicity testing is expensive, time consuming and uses a significant number of animals.

CompTox conducts innovative research that integrates advances in molecular biology, chemistry and computer science to more effectively and efficiently rank chemicals based on risk. The outcome from this research is rapid chemical screening data from the [ToxCast](#) research effort and other decision support tools that assess chemicals for potential risks to humans and the environment. EPA launched ToxCast in 2007 to develop ways to predict potential toxicity and to develop a cost-effective approach for prioritizing the thousands of chemicals that need toxicity testing. Toxcast uses advanced science tools to help understand how human body processes are impacted by exposures to chemicals and helps determine which exposures are most likely to lead to adverse health effects. Toxcast includes over 650 state-of-the-art rapid tests (called high-throughput assays) that are screening 2,000 environmental chemicals for potential toxicity.

FORWARD LOOKING STATEMENTS — *Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.*